“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,00...

As valuation looks comfortable, market experts believe it is a good time to enter the market at current valuation and reap the benefits of ...

In FY16, the top five — Sun Pharma, Dr Reddy’s, Lupin, Aurobindo and Cipla — ran up a total bill of Rs 3,497 crore in legal and professiona...

The US business is 20% of total revenues. As the proportion of this high-margin business grows, it will help Cipla improve profitability.

For investors looking at value buys of quality stocks from a longer term perspective – Cipla may just be the right pick at this juncture.

Cipla Ltd, India's fifth-largest drugmaker by sales, reported a fall of 69 per cent in its quarterly earnings on Tuesday, far short of anal...

The deal closure, that involved approvals from the US regulatory agencies, will see Cipla vault its sales from that market to around $400 m...

In an email response seeking comment, PuraCap said its complaint was publicly available at the US District Court for the Southern District ...

The S&P BSE Sensex recouped losses after falling as much as 133 points in opening trade on Wednesday following muted trend seen in other As...

Indian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.

Acquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.

We have had a good beginning in the US since our ‘go live’ in January 2015 and we expect to continue our growth trajectory there.

India Ratings & Research today said Cipla's ratings are unlikely to be affected by the recent cash-rich acquisitions of two US-based compan...

Cipla has acquired a portfolio of largely plain vanilla oral solids where its capabilities are already well-established, and hence the acqu...

Cipla said the group, through its subsidiary Camber Pharmaceuticals Inc., will continue to strengthen its operations in the US.

Cipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...

Cipla shares climbed over 3% in morning trade after the company said its UK-based subsidiary, Cipla EU, will acquire two US-based companies.